The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on August 20, Bonasia (Hangzhou) Pharmaceutical Technology Co., Ltd. (Bonasia for short) submitted a listing application to the main board of the Hong Kong Stock Exchange, with Xingzheng International and ICBC International as co-sponsors. The company submitted its listing to the Hong Kong Stock Exchange on February 11, 2026. According to the prospectus, Bonasia is a clinical contract research organization (“CRO”) organization headquartered in Hangzhou, China, dedicated to empowering clinical research through digitalization. The company's core business is to provide clinical trial technical services to domestic and foreign pharmaceutical and biotechnology companies, with the aim of accelerating the development and commercialization of chemical drugs and biological products. In 2025, among companies headquartered in China, the company ranked 14th in revenue from clinical CRO services, with a market share of 0.7%.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.